Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?

Amber Afzal, Jordan Schaefer

Research output: Contribution to journalArticlepeer-review

Abstract

A 59-year-old female with Child-Pugh class B cirrhosis attributed to nonalcoholic steatohepatitis complicated by hepatic encephalopathy, portal hypertension with esophageal varices, and thrombocytopenia is seen for management of an acute segmental right lower lobe pulmonary embolism in a clinic. She is hemodynamically stable. Complete blood count is notable for hemoglobin 11.6  g/dL and platelets 80 K/μL. Prothrombin time is 12.6 seconds; partial thromboplastin time, 33.7 seconds; and fibrinogen, 221  mg/dL. She was referred to discuss if a direct oral anticoagulant (DOAC) can be used for anticoagulation.

Original languageEnglish
Pages (from-to)289-293
Number of pages5
JournalHematology. American Society of Hematology. Education Program
Volume2023
Issue number1
DOIs
StatePublished - Dec 8 2023

Fingerprint

Dive into the research topics of 'Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?'. Together they form a unique fingerprint.

Cite this